Leflunomide plus decitabine for relapsed or refractory myelodysplastic syndromes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 1/2, dose-escalation trial testing oral leflunomide given alongside standard decitabine in 28-day cycles for adults with relapsed or refractory MDS. Decitabine is given at 20 mg/m2 IV once daily for 5 days each cycle, while leflunomide is given orally at 10–20 mg daily for 14–21 days per cycle without a loading dose. The study uses a traditional dose-escalation scheme to estimate maximum tolerated and biologically active doses and defines a 30-day window after first combination dose for determining dose-limiting toxicities. Participants will undergo bone marrow biopsies and blood monitoring at baseline and after Cycles 3, 6, and 12, and responders may continue on assigned doses beyond 12 cycles.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient has pathologically confirmed diagnosis of MDS
* Patient has currently measurable disease meeting the following criteria:

  * Bone marrow biopsy with more than 5% blasts, AND
  * Absolute neutrophil count (ANC) less than 1,000/mcL, and/or platelet count less than 100,000/mcL and/or hemoglobin levels less than 10g/dL
* Patient has received one prior treatment with a DNA methyltransferase inhibitor (DNMTi), also commonly called hypomethylating agent (HMA). Patients whose MDS has IDH1/IDH2 mutations should have received at least one available IDH1/IDH2 inhibitor
* Patient has an Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
* Patient has the following required baseline laboratory data (eligibility can be based on local lab results):

  * Total serum bilirubin level less than or equal to 2 times ULN
  * Estimated glomerular filtration rate (eGFR) greater than or equal to 45 mL/min/1.73 m2
* Patients who have undergone alloHSCT are eligible if they are more than 28 days post stem cell infusion, have no evidence of GVHD \> Grade 1, and are more than a week off all immunosuppressive therapy
* If a female of childbearing potential, the patient has a negative serum or urine pregnancy test result within 7 days prior to the first dose of treatment. Women of non-childbearing potential are those who are postmenopausal greater than one year or who have had a bilateral tubal ligation or hysterectomy
* If female of childbearing potential or a male patient, patient agrees to use an effective contraceptive method from the time of informed consent, during the course of the study, and for 3 months following the last dose of treatment
* Patient understands and voluntarily signs the written informed consent prior to any study-specific procedures. A copy of the signed informed consent form will be retained by the treating institution

Exclusion Criteria:

* Patients receiving any other investigational agents, or concurrent chemotherapy or immunotherapy
* Patients with progression to acute myeloid leukemia
* Patients with other malignancies requiring systemic chemotherapy, immunotherapy or targeted therapy in the last four weeks
* Patients with uncontrolled bacterial, viral or fungal infections (undergoing appropriate treatment and with progression of clinical symptoms)
* Patients with active or latent tuberculosis
* Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that per Principal Investigator's judgment would limit compliance with study requirements
* Females who are pregnant or breast feeding
* Any other clinical conditions that in the opinion of the investigator would make the subject unsuitable for the study

Where it's running

• West Virginia University Cancer Institute
  Morgantown, West Virginia, United States Recruiting

Study contacts

• Principal investigator: Konstantinos Sdrimas, MD — West Virginia University
• Study coordinator: Konstantinos Sdrimas, MD
• Email: Konstantinos.sdrimas1@hsc.wvu.edu
• Phone: 304-598-4520

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Age-stratified conditioning regimens to improve outcomes in haploidentical stem cell transplant for myelodysplastic syndrome

  This study tests two conditioning regimens in adults with MDS undergoing haploidentical stem cell transplant to see how age affects outcomes over one year.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07677306

• FXS0683 in relapsed or refractory blood cancers

  This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.

  Recruiting Phase 1 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Tianjin, Tianjin Municipality · NCT07616089

• Brain network changes in adults with anemia measured by fNIRS

  This project will use functional near-infrared spectroscopy (fNIRS) to see if brain network connections are altered in adults aged 18–65 who have anemia.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07578675

• Cord blood transplant for children and young adults with blood cancers.

  This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT07566377

• Reduced-intensity donor stem cell transplant with treosulfan/fludarabine and post-transplant cyclophosphamide for leukemia and MDS

  This trial tests a lower-intensity donor stem cell transplant using treosulfan plus fludarabine with post-transplant cyclophosphamide to try to reduce toxicity and prevent graft-versus-host disease in people aged 2–75 with acute leukemias or myelodysplastic syndromes.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07493538

• Electronic mindfulness-based music therapy for patients receiving stem cell transplantation

  This trial tests an eHealth mindfulness-based music therapy to see if it improves quality of life and reduces symptoms for adults undergoing stem cell transplantation.

  Recruiting University of Miami · Miami, Florida · NCT07469592

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.